Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JT Files Tapinarof Cream for Eczema, Psoriasis in Japan
Japan Tobacco on September 15 filed a new drug application for tapinarof cream, a topical aryl hydrocarbon receptor agonist licensed from Swiss partner Dermavant Sciences, for the treatment of atopic dermatitis and plaque psoriasis in Japan. The submission, announced by…
To read the full story
Related Article
- Japan Health Ministry Panel Gives Blessing to Novartis’ PNH Drug Iptacopan and More
June 4, 2024
- Tapinarof Cream Hits Main Goal in PIII Eczema Trial in Children: JT/Torii
June 3, 2024
- Novartis’ Fabhalta, Novo’s Awiqli, and More Up for PAFSC Review on May 31
May 20, 2024
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…